Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the relative efficacy and safety of the test
formulation Imiquimod 3.75% Topical Cream to the marketed formulation Zyclara® (imiquimod)
3.75% Topical Cream in the treatment of actinic keratosis. Both the test and reference
formulations will also be compared to a placebo cream to test for superiority.